Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMSI Downgrades GIANT BIOGENE to Neutral, Slashes TP to HKD34.5
Recommend 2 Positive 4 Negative 7 |
||||
|
||||
|
Due to a public relations crisis, the investment logic for GIANT BIOGENE (02367.HK) has shifted from growth to strategic adjustment, CMSI said in its research report. The company may enter an adjustment period in 2026 without any catalysts. CMSI's net profit forecast for GIANT BIOGENE is 12% lower than market expectations, and it has cut the net profit forecast by over 30% on average. GIANT BIOGENE's rating has been downgraded from Buy to Neutral, and its target price has been axed from HKD64 to HKD34.5. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
